Cytonus Therapeutics to Present Preclinical Data for Cargocyte™ CA-IL-12 for Treating Immune Checkpoint Inhibitor-Resistant Late Stage Metastatic Cancers at AACR 2022

SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics Inc. (Cytonus), a biotechnology company developing therapeutic products for targeted delivery in vivo, announces that their CSO, Dr. Richard Klemke Ph.D., will present the preclinical progress made on Cytonus’ lead Cargocyte product candidates at the annual AACR meeting in New Orleans. Cargocytes armed with interleukin 12 (CA-IL-12) can be engineered to actively home, migrate, and penetrate deep into specific disease foci and synthesize biologica
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks